ONCAlert | 2018 ASCO Annual Meeting

Dr. West Discusses Results of the Phase III FLAURA Study in NSCLC

H. Jack West, MD
Published Online: 8:31 PM, Tue September 19, 2017

H. Jack West, MD, medical oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the results of the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.